Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07024563 · ClinicalTrials.gov registry record · Phase 3
Study of Ravulizumab in Pediatric Participants With Primary IgAN
A Phase 3 study of Immunoglobulin A Nephropathy and IgA Vasculitis, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
- 14
- Study locations
NCT07024563: Recruiting Phase 3 study of Immunoglobulin A Nephropathy and IgA Vasculitis, sponsored by Alexion Pharmaceuticals.
NCT07024563 is a Phase 3 study of Immunoglobulin A Nephropathy and IgA Vasculitis that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 24 participants, below the 303-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (92% lower). The trial reports 14 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07024563, a Phase 3 study of Immunoglobulin A Nephropathy and IgA Vasculitis, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
- 14
- Study locations
Study Summary
The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or IgAVN.
Conditions Studied
Interventions
- DRUG Ravulizumab
Study Locations (14)
Other
- Research Site - Beijing
- Research Site - Shanghai
- Research Site - Genova
- Research Site - Roma
- Research Site - Torino
- Research Site - Wakayama
- Research Site - Seoul
- Research Site - Barcelona
- Research Site - Barcelona
- Research Site - Seville
- Research Site - Taipei
- Research Site - Taoyuan District
California
- Research Site - Palo Alto
Colorado
- Research Site - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-06-14 |
| Est. Completion | 2029-11-27 |
| Phase | Phase 3 |
What NCT07024563 shows while recruiting
NCT07024563 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 303-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (92% lower).
The record links to 6 conditions, with Immunoglobulin A Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which Ravulizumab is the first listed.
NCT07024563 lists 14 locations in 3 states (Other, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT07024563 about?
NCT07024563 is a clinical study titled "Study of Ravulizumab in Pediatric Participants With Primary IgAN". The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or IgAVN.
What is the current status of trial NCT07024563?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2025-06-14. Estimated completion is 2029-11-27.
What conditions does trial NCT07024563 study?
This clinical trial studies the following conditions: Immunoglobulin A Nephropathy, IgA Vasculitis, IgAN, IgAVN, Immunoglobulin A Vasculitis Associated Nephritis.
What interventions are being tested in trial NCT07024563?
The interventions under investigation include: Ravulizumab (DRUG).
Who is sponsoring clinical trial NCT07024563?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07024563 being conducted?
This trial has 14 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immunoglobulin A Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07024563's enrollment target sits among peer trials
24 13th of 13 higher than 1 of 13 other Immunoglobulin A Nephropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Immunoglobulin A Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
RECRUITING · Phase 3
-
Atrasentan in Patients With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Zigakibart in Adults With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI